RCW'12, Internet Report

NEWLY DEVELOPED NIR CONTRAST AGENTS FOR CANCER TARGETED IMAGING

Institute of Combined Injury, State Key Laboratory of Trauma, Burns and Combined Injury, Department of Preventive Medicine, Third Military Medical University, Chongqing, 400038, China

Discussion Live Chat

ABSTRACT

The development of multifunctional agents for simultaneous tumor targeting, imaging and treatment is expected to have significant impact on future personalized oncology. Current most common strategies are based on the chemical conjugation of chemical agents or nanoparticles with tumor specific ligands, such as small molecules, peptides, proteins and antibodies. However, these strategies have proven to be challenging and are still at an early or proof-of-concept stage due to several fundamental problems and technical barriers. Our recent studies have developed an alternative strategy to overcome these limitations by providing natively multifunctional heptamethine cyanine dyes with simultaneous tumor targeting and imaging capabilities without the need of chemical conjugation to targeting ligands. These dyes have unique optical and biocompatible properties and selectively accumulate in the viable tumor cells of a variety of human cancer types. We believe these natively multifunctional heptamethine cyanine dyes will broaden current concept and have promise in cancer targeted imaging and therapy.

Representing author

photo

Prof. Chunmeng Shi

Institute of Combined Injury, Chongqing
China

Page views: 1495